Fuelled by ATP, the kinesin
molecules moved the microtubles in opposite directions.
The report provides a snapshot of the global therapeutic landscape for Kinesin
Spindle Protein (KSP or Eg5)
Roles of two homotetrameric kinesins
in sea urchin embryonic cell division.
The microtubules, pre-coated with a sticky substance, pinch off polymer nanotubes from the sphere that lengthen as the kinesin
motors travel on.
In June 2001, Cytokinetics and GSK announced that they had entered into a broad strategic alliance to discover, develop and commercialize novel small molecule therapeutics targeting mitotic kinesins
for applications in the treatment of cancer and other diseases.
Further, we are reminded how the [beta]--tubulin tails may interact with kinesin
switches and the role of the [alpha]-tubulin tail in activating the kinesin
walk (Skiniotis 2004).
He and his colleagues designed the glass chips with 800-nanometer-deep channels in different traffic patterns, anchored kinesin
molecules within the channels, and pumped in a solution of microtubules.
Under the agreement terms, Eli Lilly will exclusively develop and market mitotic kinesin
Eg5 worldwide except in Japan.
has two globular motor regions, called heads, attached side by side to one end of a long tether that attaches to the load at its other end.
The scientists filled the vesicals with microtubules, tube-shaped components of the cytoskeleton, and kinesin
Specific topics include cell-receptor interactions, regulatory mechanisms of kinesin
and myosin motor proteins (inspiration of improved control of nanomachines), neuromechanics (the role of tension in neuronal growth and memory); roughness-induced superhydrophobicity, hierarchical carbon-based materials, nanotwinned hierarchical metals; in situ TEM electromechnical testing of nanowires and nanotubes, nano-cells for live-cell imaging of gene expression; and mechanics of curvilinear electronics, modeling and simulation of hierarchical protein materials, and multiscale modeling for the vascular transport of nanoparticles.
12 December 2011 - US Array BioPharma Inc (NASDAQ:ARRY) said on Friday the results of Phase I and Phase II clinical trials of its new kinesin
spindle protein (KSP) inhibitor, ARRY-520, had demonstrated good tolerance and encouraging clinical activity in heavily pre-treated patients with multiple myeloma (MM).